Susquehanna International Group, LLP Calliditas Therapeutics Ab Call Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$15.79 - $28.99 $227,376 - $417,456
14,400 New
14,400 $370,000
Q4 2022

Feb 14, 2023
SELL
$11.5 - $19.6 $3,450 - $5,880
-300 Reduced 2.83%
10,300 $175,000
Q3 2022

Nov 14, 2022
BUY
$14.12 - $22.49 $149,672 - $238,393
10,600 New
10,600 $160,000
Q1 2022

May 16, 2022
SELL
$15.14 - $25.55 $466,312 - $786,940
-30,800 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$15.04 - $26.32 $463,232 - $810,656
30,800 New
30,800 $763,000

Others Institutions Holding CALT

# of Institutions
23
Shares Held
825K
Call Options Held
8.5K
Put Options Held
26.6K
View Full List

About Calliditas Therapeutics AB

CALT Quotes by TradingView
  • Ticker CALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,624,800
  • Market Cap $1.06B
  • Description
  • Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...
More about CALT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email